EARS Profile
Auris
Medical Holding AG (EARS) is a Swiss clinical-stage biopharmaceutical
company that is focused on developing treatments for inner ear
disorders. The company's lead product candidate is AM-101, a drug
designed to treat acute inner ear tinnitus, which is characterized by
a ringing or buzzing in the ears.
Auris Medical is also
developing other product candidates, including AM-111, a drug designed
to treat acute inner ear hearing loss, and AM-125, a drug designed to
treat vertigo and dizziness associated with Meniere's disease.
Auris Medical was founded in 2003 and is headquartered in Zug,
Switzerland. The company was conducting clinical trials for its
product candidates and had not yet generated significant revenue. The
company's revenue for the fiscal year 2020 was $0.6 million,
representing a decline from $0.9 million in the previous year. Net
loss for the same period was $9.9 million, a decline from a net loss
of $17.4 million in the previous year.
Auris Medical has a
market capitalization of approximately $5 million as of my knowledge
cutoff of September 2021, and its stock is listed on the NASDAQ stock
exchange under the ticker symbol EARS.
The biopharmaceutical
industry is subject to various risks, including regulatory risks,
competitive risks, and clinical trial risks. However, Auris Medical's
focus on developing treatments for inner ear disorders and its efforts
to advance its product candidates through clinical trials should
position it for improved performance in
|
